Natalizumab Intestinal

Natalizumab is a disease-modifying drug that relieves symptoms of multiple sclerosis and Crohn's disease by reducing inflammation. Natalizumab works by blocking the adhesion of white blood cells to the intestinal mucosa. The drug can reduce the inflammatory response, thereby slowing the progression of the disease and reducing the rate of relapse. Natalizumab did not affect the absolute count of circulating neutrophils. However, natalizumab can also cause serious side effects, including infections and immune system-related problems. Therefore, before using zizumab, the potential risks and benefits should be fully discussed with your doctor, and treatment should be carried out according to your doctor's instructions.